pharmafileSeptember 29, 2018
Tag: Novartis , Kymriah , NICE
The move comes as Novartis seeks to win approval for Kymriah and find its way in the most populous country in the world.
Due to Chinese regulations, Novartis must pair up with a Chinese firm in order access the country’s market and win approval for drugs. As such the Basel-based firm has bought 9% of CBMG’s shares for $40 million.
The deal saw CBMG’s shares rise by 16% while shares in Novartis rose 0.9% as trading closed.
"For proprietary reasons, we cannot disclose our strategy in China," a spokeswoman said in an e-mail to Reuters. "However, our collaboration with CBMG is a step toward our efforts to bring Kymriah to patients in China."
Nevertheless the move signals Novartis’ push towards expansion of its global manufacturing base for one time cancer treatment Kymriah, which uses a patient’s own immune cells to combat the deadly disease.
The expansion comes after Kymriah was approved by the EMA and Britain’s cost effectiveness board NICE, for use in young people with acute lymphoblastic leukemia (ALL).
Louis Goss
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: